Literature DB >> 21317869

Osteosarcoma: a review of diagnosis, management, and treatment strategies.

David S Geller1, Richard Gorlick.   

Abstract

Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems from the extreme variability from one tumor to the next, making it unlikely that a single target approach would be able to address all or even a majority of patients. Awareness, education, and proper referral patterns serve to minimize avoidable errors in diagnosis and treatment. However, it is unlikely that these efforts alone will significantly improve survival outcomes. Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.

Entities:  

Mesh:

Year:  2010        PMID: 21317869

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  191 in total

1.  Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.

Authors:  Ling Ren; Sung-Hyeok Hong; Qing-Rong Chen; Joseph Briggs; Jessica Cassavaugh; Satish Srinivasan; Michael M Lizardo; Arnulfo Mendoza; Ashley Y Xia; Narayan Avadhani; Javed Khan; Chand Khanna
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

2.  microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.

Authors:  Xueqin Li; Xinsheng Liu; Jun Fang; Huazhuang Li; Jingchun Chen
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

4.  TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.

Authors:  Zaijun Lin; Dianwen Song; Haifeng Wei; Xinghai Yang; Tielong Liu; Wangjun Yan; Jianru Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-15       Impact factor: 4.553

5.  Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study.

Authors:  Huading Lu; Lei Zhu; Liyi Lian; Mingwei Chen; Dehai Shi; Kun Wang
Journal:  Tumour Biol       Date:  2015-02-09

Review 6.  Progress in the chemotherapeutic treatment of osteosarcoma.

Authors:  Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

7.  What sports activity levels are achieved in patients with modular tumor endoprostheses of osteosarcoma about the knee?

Authors:  Nikolaus W Lang; Gerhard M Hobusch; Philipp T Funovics; Reinhard Windhager; Jochen G Hofstaetter
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

8.  Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR.

Authors:  Song Lin; Nan-Nan Shao; Lei Fan; Xiu-Cai Ma; Fei-Fei Pu; Zeng-Wu Shao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

9.  Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population.

Authors:  Lucero Monterde-Cruz; Eric G Ramírez-Salazar; Genaro Rico-Martínez; Luis M Linares-González; Roberto Guzmán-González; Ernesto Delgado-Cedillo; Eréndira Estrada-Villaseñor; Margarita Valdés-Flores; Rafael Velázquez-Cruz; Alberto Hidalgo-Bravo
Journal:  Hum Cell       Date:  2018-06-15       Impact factor: 4.174

10.  Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma.

Authors:  Shangzeng Wang; Xiaoya Liu; Zike He; Xinfeng Chen; Wei Li
Journal:  Tumour Biol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.